Search results for: 'Microbial Contract Biomanufacturing Market'

This Frost Radar™ analyzes the competitive landscape of the antibody-drug conjugate (ADC) contract development and manufacturing organization (CDMO) market. Companies provide the foundational manufacturing and development services for what has become one of the most dynamic and valuable therapeutic modalities in oncology. The success of the ADC rev...

Buildings are becoming more energy-intensive and with features like electric vehicle charging adding to the existing load, the need to reduce energy consumption acquires an even greater importance. Energy saving and performance contracting (ESPC) is one way to achieve energy efficiency. In that sense, North America has been the second-largest marke...

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...

21 Mar 2025  |  Global  |  Market Research

Pharmaceutical Clinical Contract Peripheral Services, Global, 2025–2030

The CRO Industry is Witnessing Transformational Growth Due to Industry Convergence and an Increasing Reliance on the Functional Service Provider (FSP) Model

Infographics

×

As trial volumes normalize after the COVID-19 pandemic, pharma and biopharma companies are re-focusing on their drug development pipelines. As a result, the market has been creating an increasing number of clinical trial outsourcing opportunities for CROs, with these service providers also refining their processes to ensure better clinical trial tu...

The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward specialized development and manufacturing capabilities ...

Europe’s life sciences sector is approaching a defining inflection point in 2026, as major regulatory and policy reforms converge to reshape pharma, diagnostics, life sciences IT, biotechnology, and the bioeconomy. Together, these frameworks open clear growth pathways across the value chain: the Clinical Trials Regulation (CTR) and European Health ...

More than 6,000 molecules are currently in clinical development across the pharmaceutical research and development (R&D) landscape, with more than 11,000 in the preclinical phase. The industry is witnessing the growth of small- to mid-segment pharma/biotech players making significant contributions to drug discovery and development pipelines. Across...

Frost & Sullivan provides comprehensive insights into the global biologics contract development and manufacturing organization (bio-CDMO) market, including emerging trends, growth opportunities, and profiles of leading bio-CDMOs and their business model evolution. The growth of next-generation biologics and personalized therapies and the emergence ...

This edition of the Industrial Bioprocessing TOE features information on innovations in endophytic microbial nitrogen fixation, advanced fermentation, sustainable packaging, modular plasma system, biomass valorization, sustainable protein, advanced cathode material upcycling, among others.The Industrial Bioprocessing TOE provides intelligence on te...